Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof

- Bracco International B.V.

One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

This application is a continuation-in-part of Ser. No. 07/695,343, filed May 3, 1991, now abandoned, which claims the benefit of EP 90810367.4, filed May 18, 1990. This application is also a continuation-in-part of Ser. No. 07/775,989, filed Nov. 20, 1991, now U.S. Pat. No. 5,271,928, which claims the benefit of PCT/EP91/00620, filed Apr. 2, 1991, and EP 90810262.7, filed Apr. 2, 1990. This application also claims the benefit of EP 92810046.0, filed Jan. 24, 1992.

TECHNICAL FIELD

The present invention concerns stable dispersions or compositions of gas filled microvesicles in aqueous carrier liquids. These dispersions are generally usable for most kinds of applications requiring gases homogeneously disperscd in liquids. One notable application for such dispersions is to be injected into living beings, for instance for ultrasonic echography and other medical applications. The invention also concerns the methods for making the foregoing compositions including some materials involved in the preparations, for instance pressure-resistant gas-filled microbubbles, microcapsules and microballoons.

BACKGROUND OF INVENTION

It is well known that microbodies or microglobules of air or gas (defined here as microvesicles), e.g. microbubbles or microballoons, suspended in a liquid are exceptionally efficient ultrasound reflectors for echography. In this disclosure the term of “microbubble” specifically designates hollow spheres or globules, filled with air or a gas, in suspension in a liquid which generally result from the introduction therein of air or gas in divided form, the liquid preferably also containing surfactants or tensides to control the surface properties and the stability of the bubbles. The term of “microcapsule” or “microballoon” designates preferably air or gas-filled bodies with a material boundary or envelope, i.e. a polymer membrane wall. Both microbubbles and microballoons are useful as ultrasonic contrast agents. For instance injecting into the bloodstream of living bodies suspensions of air-filled microbubbles or microballoons (in the range of 0.5 to 10 μm) in a carrier liquid will strongly reinforce ultrasonic echography imaging, thus aiding in the visualization of internal organs. Imaging of vessels and internal organs can strongly help in medical diagnosis, for instance for the detection of cardiovascular and other diseases.

The formation of suspensions of microbubbles in an injectable liquid carrier suitable for echography can be produced by the release of a gas dissolved under pressure in this liquid, or by a chemical reaction generating gaseous products, or by admixing with the liquid soluble or insoluble solids containing air or gas trapped or adsorbed therein.

For instance, in U.S. Pat. No. 4,446,442 (Schering), there are disclosed a series of different techniques for producing suspensions of gas microbubbles in a sterilized injectable liquid carrier using (a) a solution of a tenside (surfactant) in a carrier liquid (aqueous) and (b) a solution of a viscosity enhancer as stabilizer. For generating the bubbles, the techniques disclosed there include forcing at high velocity a mixture of (a), (b) and air through a small aperture; or injecting (a) into (b) shortly before use together with a physiologically acceptable gas; or adding an acid to (a) and a carbonate to (b), both components being mixed together just before use and the acid reacting with the carbonate to generate CO2 bubbles; or adding an over-pressurized gas to a mixture of (a) and (b) under storage, said gas being released into microbubbles at the time when the mixture is used for injection.

EP-A-131,540 (Schering) discloses the preparation of microbubble suspensions in which a stabilized injectable carrier liquid, e.g. a physiological aqueous solution of salt, or a solution of a sugar like maltose, dextrose, lactose or galactose, is mixed with solid microparticles (in the 0.1 to 1 μm range) of the same sugars containing entrapped air. In order to develop the suspension of bubbles in the liquid carrier, both liquid and solid components are agitated together under sterile conditions for a few seconds and, once made, the suspension must then be used immediately, i.e. it should be injected within 5-10 minutes for echographic measurements; indeed, because they are evanescent, the bubble concentration becomes too low for being practical after that period.

In an attempt to cure the evanescence problem, microballoons, i.e. microvesicles with a material wall, have been developed. As said before, while the microbubbles only have an immaterial or evanescent envelope, i.e. they are only surrounded by a wall of liquid Whose surface tension is being modified by the presence of a surfactant, the microballoons or microcapsules have a tangible envelope made of substantive material, e.g. a polymeric membrane with definite mechanical strength. In other terms, they are microvesicles of material in which the air or gas is more or less tightly encapsulated.

For instance, U.S. Pat. No. 4,276,885 (Tickner et al.) discloses using surface membrane microcapsules containing a gas for enhancing ultrasonic images, the membrane including a multiplicity of non-toxic and non-antigenic organic molecules. In a disclosed embodiment, these microbubbles have a gelatine membrane which resists coalescence and their preferred size is 5-10 μm. The membrane of these microbubbles is said to be sufficiently stable for making echographic measurements.

Air-filled microballoons without gelatin are disclosed in U.S. Pat. No. 4,718,433 (Feinstein). These microvesicles are made by sonication (5 to 30 kHz) of protein solutions like 5% serum albumin and have diameters in the 2-20 μm range, manly 2-4 μm. The microvesicles are stabilized by denaturation of the membrane forming protein after sonication, for instance by using heat or by chemical means, e.g. by reaction with formaldehyde or glutaraldehyde. The concentration of stable microvesicles obtained by this technique is said to be about 8×106/ml in the 2-4 μm range, about 106/ml in the 4-5 μm range and less than 5×105 in the 5-6 μm range. The stability time of these microvesicles is said to be 48 hrs or longer and they permit convenient left heart imaging after intravenous injection. For instance, the sonicated albumin microbubbles when injected into a peripheral vein are capable of transpulmonary passage. This results in echocardiographic opacification of the left ventricle cavity as well as myocardial tissues.

Recently, still further improved microballoons for injection ultrasonic echography have been reported in EP-A-324.938 (Widder). In this document there are disclosed high concentrations (more than 108/ml) of air-filled protein-bounded microvesicles of less than 10 μm which have life-times of several months or more. Aqueous suspensions of these microballoons are produced by ultrasonic cavitation of solutions of heat denaturable proteins, e.g. human serum albumin, which operation also leads to a degree of foaming of the membrane-forming protein and its subsequent hardening by heat. Other proteins such as hemoglobin and collagen were also said to be convenient in this process. The high storage stability of the suspensions of microballoons disclosed in EP-A-324.938 enables them to be marketed as such, i.e. with the liquid carrier phase, which is a strong commercial asset since preparation before use is no longer necessary.

Similar advantages have been recently discovered in connection with the preparation of aqueous microbubble suspensions, i.e. there has been discovered storage-stable dry pulverulent composition which will generate long-lasting bubble suspensions upon the addition of water. This is being disclosed in Application PCT/EP 91/00620 where liposomes comprising membrane-forming lipids are freeze-dried, and the freeze-dried lipids, after exposure to air or a gas for a period of time, will produce long-lasting bubble suspensions upon simple addition thereto of an aqueous liquid carrier.

Despite the many progresses achieved regarding the stability under storage of aqueous microbubble suspensions, this being either in the precursor or final preparation stage, there still remained until now the problem of vesicle durability when the suspensions are exposed to overpressure, e.g. pressure variations such as that occurring after injection in the blood stream of a patient and consecutive to heart pulses, particularly in the left ventricle. Actually, the present inventors have observed that, for instance in anaesthetised rabbits, the pressure variations are not sufficient to substantially alter the bubble count for a period of time after injection. In contrast, in dogs and human patients, typical microbubbles or microballoons filled with common gases such as air, methane or CO2 will collapse completely in a matter of seconds after injection due to the blood pressure effect. This observation has been confirmed by others: For instance, S. GOTTLIEB et al. in J. Am. Soc. of Echocardiography 3 (1990) 238 have reported that cross-linked albumin microballoons prepared by the sonication method were losing all echogenic properties after being subjected to an overpressure of 60 Torr. It became hence important to solve the problem and to increase the useful life of suspensions of microbubbles and membrane bounded microballoons under pressure in order to ensure that echographic measurements can be performed in vivo safely and reproducibly.

It should be mentioned at this stage that another category of echogenic image enhancing agents has been proposed which resist overpressures as they consist of plain microspheres with a porous structure, such porosity containing air or a gas. Such microspheres are disclosed for instance in WO-A-91/12823 (DELTA BIOTECHNOLOGY), EP-A-327 490 (SCHERING) and EP-A-458 079 (HOECHST). The drawback with the plain porous microspheres is that the encapsulated gas-filled free space is generally too small for good echogenic response and the spheres lack adequate elasticity. Hence the preference generally remains with the hollow microvesicles and a solution to the collapsing problem was searched.

DISCLOSURE OF THE INVENTION

This problem has now been solved by using gases or gas mixtures in conformity with the criteria outlined in the claims. Briefly, it has been found that when the echogenic microvesicles are made in the presence of a gas, respectively are filled at least in part with a gas, having physical properties in conformity with the equation below, then the microvesicles remarkably resist pressure >60 Torr after injection for a time sufficient to obtain reproducible echographic measurements: s gas s air × √ Mw air √ Mw gas ≦ 1

In the foregoing equation, “s” designates the solubilities in water expressed as the “BUNSEN” coefficients, i.e. as volume of gas dissolved by unit volume of water under standard conditions (1 bar, 25° C.), and under partial pressure of the given gas of 1 atm (see the Gas Encyclopaedia, Elsevier 1976). Since, under such conditions and definitions, the solubility of air is .0167, and the square root of its average molecular weight (Mw) is 5.39, the above relation simplifies to:
sgas/√Mwgas≦.0031

In the Examples to be found hereafter there is disclosed the testing of echogenic microbubbles and microballoons (see the Tables) filled with a number of different gases and mixtures thereof, and the corresponding resistance thereof to pressure increases, both in vivo and in vitro. In the Tables, the water solubility factors have also been taken from the aforecited Gas Encyclopaedia from “L'Air Liquide”, Elsevier Publisher (1976).

The microvesicles in aqueous suspension containing gases according to the invention include most microbubbles and microballoons disclosed until now for use as contrast agents for echography. The preferred microballoons are those disclosed in EP-A324.938, PCT/EP91/01706 and EP-A-458 745; the preferred microbubbles are those of PCT/EP91/00620; these microbubbles are advantageously formed from an aqueous liquid and a dry powder (microvesicle precursors) containing lamellarized freeze-dried phospholipids and stabilizers; the microbubbles are developed by agitation of this powder in admixture with the aqueous liquid carrier. The microballoons of EP-A-458 745 have a resilient interfacially precipitated polymer membrane of controlled porosity. They are generally obtained from emulsions into microdroplets of polymer solutions in aqueous liquids, the polymer being subsequently caused to precipitate from its solution to form a fibrogenic membrane at the droplet/liquid interface, which process leads to the initial formation of liquid-filled microvesicles, the liquid core thereof being eventually substituted by a gas.

In order to carry out the method of the present invention, i.e. to form or fill the microvesicles, whose suspensions in aqueous carriers constitute the desired echogenic additives, with the gases according to the foregoing relation, one can either use, as a first embodiment, a two step route consisting of (1) making the microvesicles from appropriate starting materials by any suitable conventional technique in the presence of any suitable gas, and (2) replacing this gas originally used (first gas) for preparing the microvesicles with a new gas (second gas) according to the invention (gas exchange technique).

Otherwise, according to a second embodiment, one can directly prepare the desired suspensions by suitable usual methods under an atmosphere of the new gas according to the invention.

If one uses the two-step route, the initial gas can be first removed from the vesicles (for instance by evacuation under suction) and thereafter replaced by bringing the second gas into contact with the evacuated product, or alternatively, the vesicles still containing the first gas can be contacted with the second gas under conditions where the second gas will displace the first gas from the vesicles (gas substitution). For instance, the vesicle suspensions, or preferably precursors thereof (precursors here may mean the materials the microvesicle envelopes are made of, or the materials which, upon agitation with an aqueous carrier liquid, will generate or develop the formation of microbubbles in this liquid), can be exposed to reduced pressure to evacuate the gas to be removed and then the ambient pressure is restored with the desired gas for substitution. This step can be repeated once or more times to ensure complete replacement of the original gas by the new one. This embodiment applies particularly well to precursor preparations stored dry, e.g. dry powders which will regenerate or develop the bubbles of the echogenic additive upon admixing with an amount of carrier liquid. Hence, in one preferred case where microbubbles are to be formed from an aqueous phase and dry laminarized phospholipids, e.g. powders of dehydrated lyophilized liposomes plus stabilizers, which powders are to be subsequently dispersed under agitation in a liquid aqueous carrier phase, it is advantageous to store this dry powder under an atmosphere of a gas selected according to the invention. A preparation of such kind will keep indefinitely in this state and can be used at any time for diagnosis, provided it is dispersed into sterile water before injection.

Otherwise, and this is particularly so when the gas exchange is applied to a suspension of microvesicles in a liquid carrier phase, the latter is flushed with the second gas until the replacement (partial or complete) is sufficient for the desired purpose. Flushing can be effected by bubbling from a gas pipe or, in some cases, by simply sweeping the surface of the liquid containing the vesicles under gentle agitation with a stream (continuous or discontinuous) of the new gas. In this case, the replacement gas can be added only once in the flask containing the suspension and allowed to stand as such for a while, or it can be renewed one or more times in order to assure that the degree of renewal (gas exchange) is more or less complete.

Alternatively, in a second embodiment as said before, one will effect the full preparation of the suspension of the echogenic additives starting with the usual precursors thereof (starting materials), as recited in the prior art and operating according to usual means of said prior art, but in the presence of the desired gases or mixture of gases according to the invention instead of that of the prior art which usually recites gases such as air, nitrogen, CO2 and the like.

It should be noted that in general the preparation mode involving one first type of gas for preparing the microvesicles and, thereafter, substituting the original gas by a second kind of gas, the latter being intended to confer different echogenic properties to said microvesicles, has the following advantage: As will be best seen from the results in the Examples hereinafter, the nature of the gas used for making the microvesicles, particularly the microballoons with a polymer envelope, has a definitive influence on the overall size (i.e. the average mean diameter) of said microvesicles; for instance, the size of microballoons prepared under air with precisely set conditions can be accurately controlled to fall within a desired range, e.g. the 1 to 10 μm range suitable for echographying the left and right heart ventricles. This not so easy with other gases, particularly the gases in conformity with the requirements of the present invention; hence, when one wishes to obtain microvesicles in a given size range but filled with gases the nature of which would render the direct preparation impossible or very hard, one will much advantageously rely on the two-steps preparation route, i.e. one will first prepare the microvesicles with a gas allowing more accurate diameter and count control, and thereafter replace the first gas by a second gas by gas exchange.

In the description of the Experimental part that follows (Examples), gas-filled microvesicles suspended in water or other aqueous solutions have been subjected to pressures over that of ambient. It was noted that when the overpressure reached a certain value (which is generally typical for a set of microsphere parameters and working conditions like temperature, compression rate, nature of carrier liquid and its content of dissolved gas (the relative importance of this parameter will be detailed hereinafter), nature of gas filler, type of echogenic material, etc.), the microvesicles started to collapse, the bubble count progressively decreasing with further increasing the pressure until a complete disappearance of the sound reflector effect occurred. This phenomenon was better followed optically, (nephelometric measurements) since it is paralleled by a corresponding change in optical density, i.e. the transparency of the medium increases as the bubble progressively collapse. For this, the aqueous suspension of microvesicles (or an appropriate dilution thereof was placed in a spectrophotometric cell maintained at 25° C. (standard conditions) and the absorbance was measured continuously at 600 or 700 nm, while a positive hydrostatic overpressure was applied and gradually increased. The pressure was generated by means of a peristaltic pump (GILSON's Mlni-puls) feeding a variable height liquid column connected to the spectrophotometric cell, the latter being sealed leak-proof. The pressure was measured with a mercury manometer calibrated in Torr. The compression rate with time was found to be linearly correlated with the pump's speed (rpm's). The absorbance in the foregoing range was found to be proportional to the microvesicle concentration in the carrier liquid.

BRIEF DESCRIPTION OF THE DRAWING

The invention will now be further described with reference to FIG. 1 which is a graph which relates the bubble concentration (bubble count), expressed in terms of optical density in the aforementioned range, and the pressure applied over the bubble suspension. The data for preparing the graph are taken from the experiments reported in Example 4.

FIG. 1 shows graphically that the change of absorbance versus pressure is represented by a sigmoid-shaped curve. Up to a certain pressure value, the curve is nearly fiat which indicates that the bubbles are stable. Then, a relatively fast absorbance drop occurs, which indicates the existence of a relatively narrow critical region within which any pressure increase has a rather dramatic effect on the bubble count. When all the microvesicles have disappeared, the curve levels off again. A critical point on this curve was selected in the middle between the higher and lower optical readings, i.e. intermediate between the “full”-bubble (OD max) and the “no”-bubble (OD min) measurements, this actually corresponding where about 50% of the bubbles initially present have disappeared, i.e. where the optical density reading is about half the initial reading, this being set, in the graph, relative to the height at which the transparency of the pressurized suspension is maximal (base line). This point which is also in the vicinity where the slope of the curve is maximal is defined as the critical pressure PC. It was found that for a given gas, PC does not only depend on the aforementioned parameters but also, and particularly so, on the actual concentration of gas (or gases) already dissolved in the carrier liquid: the higher the gas concentration, the higher the critical pressure. In this connection, one can therefore increase the resistance to collapse under pressure of the microvesicles by making the carrier phase saturated with a soluble gas, the latter being the same, or not, (i.e. a different gas) as the one that fills the vesicles. As an example, air-filled microvesicles could be made very resistant to overpressures (>120 Torr) by using, as a carrier liquid, a saturated solution of CO2. Unfortunately, this finding is of limited value in the diagnostic field since once the contrast agent is injected to the bloodstream of patients (the gas content of which is of course outside control), it becomes diluted therein to such an extent that the effect of the gas originally dissolved in the injected sample becomes negligible.

Another readily accessible parameter to reproducibly compare the performance of various gases as microsphere fillers is the width of the pressure interval (ΔP) limited by the pressure values under which the bubble counts (as expressed by the optical densities) is equal to the 75% and 25% of the original bubble count. Now, it has been surprisingly found that for gases where the pressure difference DP=P25-P75 exceeds a value of about 25-30 Torr, the killing effect of the blood pressure on the gas-filled microvesicles is minimized, i.e. the actual decrease in the bubble count is sufficiently slow not to impair the significance, accuracy and reproducibility of echographic measurements.

It was found, in addition, that the values of PC and ΔP also depend on the rate of rising the pressure in the test experiments illustrated by FIG. 1, i.e. in a certain interval of pressure increase rates (e.g. in the range of several tens to several hundreds of Torr/min), the higher the rate, the larger the values for PC and ΔP. For this reason, the comparisons effected under standard temperature conditions were also carried out at the constant increase rate of 100 Torr/min. It should however be noted that this effect of the pressure increase rate on the measure of the PC and ΔP values levels off for very high rates; for instance the values measured under rates of several hundreds of Torr/min are not significantly different from those measured under conditions ruled by heart beats.

Although the very reasons why certain gases obey the aforementioned properties, while others do not, have not been entirely clarified, it would appear that some relation possibly exists in which, in addition to molecular weight and water solubility, dissolution kinetics, and perhaps other parameters, are involved. However these parameters need not be known to practise the present invention since gas eligibility can be easily determined according to the aforediscussed criteria.

The gaseous species which particularly suit the invention are, for instance, halogenated hydrocarbons like the freons and stable fluorinated chalcogenides like SF6, SeF6 and the like.

It has been mentioned above that the degree of gas saturation of the liquid used as carrier for the microvesicles according to the invention has an importance on the vesicle stability under pressure variations. Indeed, when the carrier liquid in which the microvesicles are dispersed for making the echogenic suspensions of the invention is saturated at equilibrium with a gas, preferably the same gas with which the microvesicles are filled, the resistance of the microvesicles to collapse under variations of pressure is markedly increased. Thus, when the product to be used as a contrast agent is sold dry to be mixed Just before use with the carrier liquid (see for instance the products disclosed in PCT/EP91/00620 mentioned hereinbefore), it is quite advantageous to use, for the dispersion, a gas saturated aqueous carrier. Alternatively, when marketing ready-to-use microvesicle suspensions as contrast agents for echography, one will advantageously use as the carrier liquid for the preparation a gas saturated aqueous solution; in this case the storage life of the suspension will be considerably increased and the product may be kept substantially unchanged (no substantial bubble count variation) for extended periods, for instance several weeks to several months, and even over a year in special cases. Saturation of the liquid with a gas may be effected most easily by simply bubbling the gas into the liquid for a period of time at room temperature.

EXAMPLE 1

Albumin microvesicles filled with air or various gases were prepared as described in EP-A- 324 938 using a 10 ml calibrated syringe filled with a 5% human serum albumin (HSA) obtained from the Blood Transfusion Service, Red-Cross Organization, Bern, Switzerland. A sonicator probe (Sonifier Model 250 from Branson Ultrasonic Corp, USA) was lowered into the solution down to the 4 ml mark of the syringe and sonication was effected for 25 sec (energy setting =8). Then the sonicator probe was raised above the solution level up to the 6 ml mark and sonication was resumed under the pulse mode (cycle=0.3) for 40 sec. After standing overnight at 4° C., a top layer containing most of the microvesicles had formed by buoyancy and the bottom layer containing unused albumin debris of denatured protein and other insolubles was discarded. After resuspending the microvesicles in fresh albumin solution the mixture was allowed to settle again at room temperature and the upper layer was finally collected. When the foregoing sequences were carried out under the ambient atmosphere, air filled microballoons were obtained. For obtaining microballoons filled with other gases, the albumin solution was first purged with a new gas, then the foregoing operational sequences were effected under a stream of this gas flowing on the surface of the solution; then at the end of the operations, the suspension was placed in a glass bottle which was extensively purged with the desired gas before sealing.

The various suspensions of microballoons filled with different gases were diluted to 1:10 with distilled water saturated at equilibrium with air, then they were placed in an optical cell as described above and the absorbance was recorded while increasing steadily the pressure over the suspension. During the measurements, the suspensions temperature was kept at 25° C.

The results are shown in the Table 1 below and are expressed in terms of the critical pressure PC values registered for a series of gases defined by names or formulae, the characteristic parameters of such gases, i.e. Mw and water solubility being given, as well as the original bubble count and bubble average size (mean diameter in volume).

TABLE 1 Bubble Bubble Solu- count size Sgas/V Sample Gas Mw bility (108/ml) (μm) PC (Torr) Mw AFre1 CF4 88 .0038 0.8 5.1 120 .0004 AFre2 CBrF3 149 .0045 0.1 11.1 104 .0004 ASF1 SF6 146 .005 13.9 6.2 150 .0004 ASF2 SF6 146 .005 2.0 7.9 140 .0004 AN1 N2 28 .0144 0.4 7.8 62 .0027 A14 Air 29 .0167 3.1 11.9 53 .0031 A18 Air 29 .0167 3.8 9.2 52 — A19 Air 29 .0167 1.9 9.5 51 — AMe1 CH4 16 .032 0.25 8.2 34 .008 AKr1 Kr 84 .059 0.02 9.2 86 .006 AX1 Xe 131 .108 0.06 17.2 65 .009 AX2 Xe 131 .108 0.03 16.5 89 .009

From the results of Table 1, it is seen that the critical pressure PC increases for gases of lower solubility and higher molecular weight. It can therefore be expected that microvesicles filled with such gases will provide more durable echogenic signals in vivo. It can also be seen that average bubble size generally increases with gas solubility.

EXAMPLE 2

Aliquots (1 ml) of some of the microballoon suspensions prepared in Example 1 were injected in the Jugular vein of experimental rabbits in order to test echogenicity in vivo. Imaging of the left and right heart ventricles was carried out in the grey scale mode using an Acuson 128-XP5 echography apparatus and a 7.5 MHz transducer. The duration of contrast enhancement in the left ventricle was determined by recording the signal for a period of time. The results are gathered in Table 2 below which also shows the PC of the gases used.

TABLE 2 Duration of Sample (Gas) contrast (sec) PC (Torr) AMcl (CH4) zero 34 A14 (air) 10 53 A18 (air) 11 52 AX1 (Xe) 20 65 AX2 (Xe) 30 89 ASF2(SF6) >60 140

From the above results, one can see the existence of a definite correlation between the critical pressure of the gases tried and the persistence in time of the echogenic signal.

EXAMPLE 3

A suspension of echogenic air-filled galactose microparticles (Echovist® from SCHERING AG) was obtained by shaking for 5 sec 3 g of the solid microparticles in 8.5 ml of a 20% galactose solution. In other preparations, the air above a portion of Echovist® particles was evacuated (0.2 Torr) and replaced by an SF6 atmosphere, whereby, after addition of the 20% galactose solution, a suspension of microparticles containing associated sulfur hexafluoride was obtained. Aliquots (1 ml) of the suspensions were administered to experimental rabbits (by injection in the jugular vein) and imaging of the heart was effected as described in the previous example. In this case the echogenic microparticles do not transit through the lung capillaries, hence imaging is restricted to the right ventricle and the overall signal persistence has no particular significance. The results of Table 3 below show the value of signal peak intensity a few seconds after injection.

TABLE 3 Signal peak Sample No Gas (arbitrary units) Gal1 air 114 Gal2 air 108 Gal3 SF6 131 Gal4 SF6 140

It can be seen that sulfur hexafluoride, an inert gas with low water solubility, provides echogenic suspensions which generate echogenic signals stronger than comparable suspensions filled with air. These results are particularly interesting in view of the teachings of EP-A-441 468 and 357 163 (SCHERING) which disclose the use for echography purposes of microparticles, respectively, cavitate and clathrate compounds filled with various gases including SF6; these documents do not however report particular advantages of SF6 over other more common gases with regard to the echogenic response.

EXAMPLE 4

A series of echogenic suspensions of gas-filled microbubbles were prepared by the general method set forth below:

One gram of a mixture of hydrogenated soya lecithin (from Nattermann Phospholipids GmbH, Germany) and dicetyl-phosphate (DCP), in 9/1 molar ratio, was dissolved in 50 ml of chloroform, and the solution was placed in a 100 ml round flask and evaporated to dryness on a Rotavapor apparatus. Then, 20 ml of distilled water were added and the mixture was slowly agitated at 75° C. for an hour. This resulted in the formation of a suspension of multilamellar liposomes (MLV) which was thereafter extruded at 75° C. through, successively, 3 μm and 0.8 μm polycarbonate membranes (Nuclepore(D). After cooling, 1 ml aliquots of the extruded suspension were diluted with 9 ml of a concentrated lactose solution (83 g/l), and the diluted suspensions were frozen at −45° C. The frozen samples were thereafter freeze-dried under high vacuum to a free-flowing powder in a vessel which was ultimately filled with air or a gas taken from a selection of gases as indicated in Table 4 below. The powdery samples were then resuspended in 10 ml of water as the carrier liquid, this being effected under a stream of the same gas used to fill the said vessels. Suspension was effected by vigorously shaking for 1 min on a vortex mixer.

The various suspensions were diluted 1:20 with distilled water equilibrated beforehand with air at 25° C. and the dilutions were then pressure tested at 25° C. as disclosed in Example 1 by measuring the optical density in a spectrophotometric cell which was subjected to a progressively increasing hydrostatic pressure until all bubbles had collapsed. The results are collected in Table 4 below which, in addition to the critical pressure PC, gives also the ΔP values (see FIG. 1).

TABLE 4 Bubble Sample Solubility count PC ΔP No Gas Mw in H2O (108/ml) (Torr) (Torr) LFre1 CF4 88 .0038  1.2 97 35 LFre2 CBrF3 149 .0045  0.9 116 64 LSF1 SF6 146 .005  1.2 92 58 LFre3 C4F8 200 .016  1.5 136 145 L1 air 29 .0167 15.5 68 17 L2 air 29 .0167 11.2 63 17 LAr1 Ar 40 .031 14.5 71 18 LKr1 Kr 84 .059 12.2 86 18 LXel Xe 131 .108 10.1 92 23 LFre4 CHClF2 86 .78 — 83 25

The foregoing results clearly indicate that the highest resistance to pressure increases is provided by the most water-insoluble gases. The behavior of the microbubbles is therefore similar to that of the microballoons in this regard. Also, the less water-soluble gases with the higher molecular weights provide the flattest bubble-collapse/pressure curves (i.e. ΔP is the widest) which is also an important factor of echogenic response durability in vivo, as indicated hereinbefore.

EXAMPLE 5

Some of the microbubble suspensions of Example 4 were injected to the jugular vein of experimental rabbits as indicated in Example 2 and imaging of the left heart ventricle was effected as indicated previously. The duration of the period for which a useful echogenic signal was detected was recorded and the results are shown in Table 5 below in which C4F8 indicates octafluorocyclobutane.

TABLE 5 Contrast duration Sample No Type of gas (scc) L.1 Air 38 L.2 Air 29 LMeI CH4 47 LKrI Krypton 37 LFre1 CF4 >120 LFre1 CBrF3 92 LSF1 SF6 >112 LFre3 C4F8 >120

These results indicate that, again in the case of microbubbles, the gases according to the criteria of the present invention will provide ultrasonic echo signal for a much longer period than most gases used until now.

EXAMPLE 6

Suspensions of microbubbles were prepared using different gases exactly as described in Example 4, but replacing the lecithin phospholipid ingredient by a mole equivalent of diarachidoylphosphatidylcholine (C20 fatty acid residue) available from Avanti Polar Lipids, Birmingham, Ala. USA. The phospholipid to DCP molar ratio was still 9/1. Then the suspensions were pressure tested as in Example 4; the results, collected in Table 6A below, are to be compared with those of Table 4.

TABLE 6A Bubble Sample Type of Mw of Solubility count PC ΔP No gas gas in water (108/ml) (Torr) (Torr) LFre1 CF4 88 .0038 3.4 251 124 LFre2 CBrF3 149 .0045 0.7 121 74 LSF1 SF6 146 .005 3.1 347 >150 LFre3 C4F8 200 .016 1.7 >350 >200 L1 Air 29 .0167 3.8 60 22 LBu1 Butane 58 .027 0.4 64 26 LAr1 Argon 40 .031 3.3 84 47 LMe1 CH4 16 .032 3.0 51 19 LEt1 C2H6 44 .034 1.4 61 26 LKr1 Kr 84 .059 2.7 63 18 LXe1 Xe 131 .108 1.4 60 28 LFre4 CHClF2 86 .78 0.4 58 28

The above results, compared to that of Table 4, show that, at least with low solubility gases, by lengthening the chain of the phospholipid fatty acid residues, one can dramatically increase the stability of the echogenic suspension toward pressure increases. This was further confirmed by repeating the foregoing experiments but replacing the phospholipid component by its higher homolog, i.e. di-behenoylphosphatidylcholine (C22 fatty acid residue). In this case, the resistance to collapse with pressure of the microbubbles suspensions was still further increased.

Some of the microbubbles suspensions of this Example were tested in dogs as described previously for rabbits (imaging of the heart ventricles after injection of 5 ml samples in the anterior cephalic vein). A significant enhancement of the useful in-vivo echogenic response was noted, in comparison with the behavior of the preparations disclosed in Example 4, i.e. the increase in chain length of the fatty-acid residue in the phospholipid component increases the useful life of the echogenic agent in-vivo.

In the next Table below, there is shown the relative stability in the left ventricle of the rabbit of microbubbles (SF6) prepared from suspensions of a series of phospholipids whose fatty acid residues have different chain lengths (<injected dose: 1 ml/rabbit).

TABLE 6B Duration of Chain length PC ΔP contrast Phospholipid (Cn) (Torr) (Torr) (sec) DMPC 14 57 37 31 DPPC 16 100 76 105 DSPC 18 115 95 120 DAPC 20 266 190 >300

It has been mentioned hereinabove that for the measurement of resistance to pressure described in these Examples, a constant rate of pressure rise of 100 Torr/min was maintained. This is justified by the results given below which show the variations of the PC values for different gases in function to the rate of pressure increase. In these samples DMPC was the phospholipid used.

PC (Torr) Gas Rate of pressure increase (Torr/min) sample 40 100 200 SF6 51 57 82 Air 39 50 62 CH4 47 61 69 Xe 38 43 51 Freon 22 37 54 67

EXAMPLE 7

A series of albumin microballoons as suspensions in water were prepared under air in a controlled sphere size fashion using the directions given in Example 1. Then the air in some of the samples was replaced by other gases by the gas-exchange sweep method at ambient pressure. Then, after diluting to 1:10 with distilled water as usual, the samples were subjected to pressure testing as in Example 1. From the results gathered in Table 7 below, it can be seen that the two-steps preparation mode gives, in some cases, echo-generating agents with better resistance to pressure than the one-step preparation mode of Example 1.

TABLE 7 Initial bubble Sample Type of Mw of the Solubility count PC No gas gas in water (108/ml) (Torr) A14 Air 29 .0167 3.1 53 A18 Air 29 .0167 3.8 52 A18/SF6 SF6 146 .005 0.8 115 A18/C2H4 C2H6 30 .042 3.4 72 A19 Air 29 .0167 1.5 51 A19/SF6 SF6 146 .005 0.6 140 A19/Xe Xe 131 .108 1.3 67 A22/CF4 CF4 88 .0018 1.0 167 A22/Kr Kr 84 .059 0.6 85

EXAMPLE 8

The method of the present invention was applied to an experiment as disclosed in the prior art, for instance Example 1 WO-92/11873. Three grams of Pluronic® F68 (a copolymer of polyoxyethylene-polyoxypropylene with a molecular weight of 8400), 1 g of dipalmitoylphosphatidylglycerol (Na salt, AVANTI Polar Lipids) and 3.6 g of glycerol were added to 80 ml of distilled water. After heating at about 80° C., a clear homogenous solution was obtained. The tenside solution was cooled to room temperature and the volume was adjusted to 100 ml. In some experiments (see Table 8) dipalmitoylphosphatidylglycerol was replaced by a mixture of diarachidoylphosphatldylcholine (920 mg) and 80 mg of dipalmitoylphosphatidic acid (Na salt, AVANTI Polar lipids).

The bubble suspensions were obtained by using two syringes connected via a three-way valve. One of the syringes was filled with 5 ml of the tenside solution while the other was filled with 0.5 ml of air or gas. The three-way valve was filled with the tenside solution before it was connected to the gas-containing syringe. By alternatively operating the two pistons, the tenside solutions were transferred back and forth between the two syringes (5 times in each direction), milky suspensions were formed. After dilution (1:10 to 1:50) with distilled water saturated at equilibrium with air, the resistance to pressure of the preparations was determined according to Example 1, the pressure increase rate was 240 Torr/min. The following results were obtained:

TABLE 8 Phospholipid Gas Pc (mm Hg) DP (mm Hg) DPPG air 28 17 DPPG SF6 138 134 DAPC/DPPA 9/1 air 46 30 DAPC/DPPA 9/1 SF6 269 253

It follows that by using the method of the invention and replacing air with other gases, e.g. SF6 even with known preparations a considerable improvements i.e. increase in the resistance to pressure may be achieved. this is true both in the case of negatively charged phospholipids (e.g. DPPG) and in the case of mixtures of neutral and negatively charged phospholipids (DAPC/DPPA).

The above experiment further demonstrates that the recognised problem sensitivity of microbubbles and microballoons to collapse when exposed to pressure i.e. when suspension are injected into living beings, has advantageously been solved by the method of the invention. Suspensions with microbubbles or microballoons with greater resistance against collapse and greater stability can advantageously be produced providing suspensions with better reproducibility and improved safety of echographic measurements performed in vivo on a human or animal body.

Claims

1. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being either microbubbles bounded by an evanescent gas/liquid interfacial closed surface, or microballoons bounded by a material envelope filled with a physiologically acceptable gas wherein the gas is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the step of forming the microvesicles in the presence of a physiologically acceptable gas, or gas mixture comprising a physiologically acceptable gas, or filling preformed microvesicles with said gas, or said gas mixture, said the physiologically acceptable gas being selected from the group consisting of SF6, SeF6, CF4, CBrF3, C4F8, CClF3, CCl2F2, C2F6, C2ClF5, CBrClF2, C2Cl2F4, CBr2F2 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is in injected into the bloodstream of a patient.

2. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carder carrier phase, the microvesicles being either microbubbles bounded by an evanescent gas/liquid interfacial closed surface, or microballoons bounded by a material envelope filled with a physiologically acceptable gas wherein the gas is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the steps of:

preforming the microvesicles or precursors thereof under an atmosphere of a first gas; and
substantially substituting at least a fraction of said first gas with a second gas which is a physiologically acceptable gas, or gas mixture comprising a physiologically acceptable gas, said the physiologically acceptable gas being selected from the group consisting of SF6, SeF6, CF4, CBrF3, C4F8, CClF3, CCl2F2, C2F6, C2ClF5, CBrClF2, C2Cl2F4, CBr2F2 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

3. The method of claim 2, in which the gas used in the first step allows effective control of the average size and concentration of the microvesicles in the carrier liquid, and the physiologically acceptable gas added in the second step ensures prolonged useful echogenic life of the suspension for in-vivo ultrasonic imaging.

4. The method of claim 1, in which the aqueous phase carrying the microbubbles contains dissolved film-forming surfactants in lamellar or laminar fog said surfactants stabilizing the microbubbles boundary at the gas/liquid innerface.

5. The method of claim 4, in which said surfactants comprise one or more phospholipids.

6. The method of claim 5, in which at least pan of the phospholipids are in the form of liposomes.

7. The method of claim 5 1, in which m at least one of the phospholipids is a diacylphosphatidyl compound wherein the acyl group is a C16 fatty acid residue or a higher homologue thereof.

8. The method of claim 1, in which the microballoon material envelope is made of an organic polymeric membrane.

9. The method of claim 8, in which the polymers of the membrane are selected from the group consisting of polylactic or polyglycolic acid and their copolymers, reticulated serum albumin, reticulated haemoglobin polystyrene, and esters of polyglutamic and polyaspanic acids.

10. The method of claim 1, in which the forming of vesicles with said physiologically acceptable gas is effected by alternately subjecting dry precursors thereof to reduced pressure and restoring the pressure with said gas, and dispersing the precursors in a liquid carrier.

11. The method of claim 1, in which the filling of the microballoons with said physiologically acceptable gas is effected by flushing the suspension with said gas under ambient pressure.

12. The method of claim 1, in which the microvesicles are made under an atmosphere composed at least in part of said gas.

13. A method of making a contrast agent for ultrasonic echography which consists of gas-filled microvesicles microbubbles suspended in an aqueous liquid carrier phase, the microvesicles microbubbles having resistance against collapse resulting from pressure increases effective when the said suspensions are injected into the bloodstream of a patient, and the microbubbles being filled with a physiologically acceptable gas wherein the gas is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the step of forming the microvesicles microbubbles in the presence of a physiologically acceptable gas or gas mixture comprising a physiologically acceptable gas, or filling preformed microvesicles with said gas or said gas mixture, said physiologically acceptable gas being selected from the group consisting of SF6, SeF6, CF4, CBrF3, C4F8, CClF3, CCl2F2, C2F6, C2ClF5, CBrClF2, C2Cl2F4, CBr2F2 and C4F10, said gas or at least a gas in said gas mixture being such that, under standard conditions, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25Torr.

14. An aqueous suspension made according to the method of claim 13, wherein the physiologically acceptable gas is such that, under standard conditions, and at a rate of pressure increase to the suspension of about 100 Torr/min, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25Torr.

15. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microbubbles filled with a gas mixture wherein the gas mixture is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the step of forming the microvesicles in the presence of the gas mixture comprising a physiologically acceptable gas, selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, and microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

16. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microballoons consisting of a physiologically acceptable gas bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the step of forming the microvesicles in the presence of said physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

17. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microballoons consisting of a gas mixture bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the step of forming the microvesicles in the presence of the gas mixture comprising a physiologically acceptable gas, selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

18. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microbubbles filled with a gas mixture wherein the gas mixture is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the steps of:

preforming the microvesicles or precursors thereof under an atmosphere of a first gas; and
substantially substituting at least a fraction of said first gas with a second gas which is the gas mixture comprising a physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

19. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microballoons consisting of a physiologically acceptable gas bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the steps of:

preforming the microvesicles or precursors thereof under an atmosphere of a first gas; and
substantially substituting at least a fraction of said first gas with a second gas which is the physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

20. A method of making a contrast agent having resistance against collapse from pressure increases when used in ultrasonic echography, said contrast agent consisting of gas-filled microvesicles suspended in an aqueous liquid carrier phase, the microvesicles being microballoons consisting of a gas mixture bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the steps of

preforming the microvesicles or precursors thereof under an atmosphere of a first gas; and
substantially substituting at least a fraction of said first gas with a second gas which is the gas mixture comprising a physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said microvesicles having resistance against collapse resulting, at least in part, from pressure increases effective when a suspension of said gas-filled microvesicles is injected into the bloodstream of a patient.

21. The method of claim 18, in which the gas used in the first step allows effective control of the average size and concentration of the microvesicles in the carrier liquid, and the physiologically acceptable gas added in the second step ensures prolonged useful echogenic life of the suspension for in-vivo ultrasonic imaging.

22. The method of claims 19 or 20, in which the gas used in the first step allows effective control of the average size and concentration of the microvesicles in the carrier liquid, and the physiologically acceptable gas added in the second step ensures prolonged useful echogenic life of the suspension for in-vivo ultrasonic imaging.

23. The method of claim 15, in which at least one of the phospholipids is a diacylphosphatidyl compound wherein the acyl group is a C16 fatty acid residue or a higher homologue thereof.

24. The method of claims 16 or 17, in which the forming of vesicles with said physiologically acceptable gas is effected by alternately subjecting dry precursors thereof to reduced pressure and restoring the pressure with said gas, and dispersing the precursors in a liquid carrier.

25. The method of claims 16 or 17, in which the filling of the microballoons with said physiologically acceptable gas is effected by flushing the suspension with said gas under ambient pressure.

26. A method of making a contrast agent for ultrasonic echography which consists of gas-filled microbubbles suspended in an aqueous liquid carrier phase, the microbubbles having resistance against collapse resulting from pressure increases effective when the said suspension are injected into the bloodstream of a patient and the microbubbles being filled with a gas mixture wherein the gas mixture is bounded by a stabilizing layer of one or more film forming phospholipids in lamellar or laminar form at the gas/liquid interface, said method comprising the step of forming the microbubbles in the presence of the gas mixture comprising a physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said gas or at least a gas in said gas mixture being such that, under standard conditions, the pressure difference ΔP between pressure at which the bubble counts are about 75% and 25% of the original bubbles count is at least 25 Torr.

27. A method of making a contrast agent for ultrasonic echography which consists of gas-filled microballoons suspended in an aqueous liquid carrier phase, the microballoons having resistance against collapse resulting from pressure increases effective when the said suspensions are injected into the bloodstream of a patient and the microballoons consisting of a physiologically acceptable gas bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the step of forming the microballoons in the presence of the physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said gas or at least a gas in said gas mixture being such that, under standard conditions, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25 Torr.

28. A method of making a contrast agent for ultrasonic echography which consists of gas-filled microballoons suspended in an aqueous liquid carrier phase, the microballoons having resistance against collapse resulting from pressure increases effective when the said suspensions are injected into the bloodstream of a patient and the microballoons consisting of a gas mixture bounded by an organic polymer envelope at the gas/liquid interface, said polymer envelope formed from one or more polymers selected from the group consisting of polylactic or polyglycolic acid and their copolymers, denatured albumin, reticulated hemoglobin, and esters of polyglutamic and polyaspartic acids, said method comprising the steps of forming the microballoons in the presence of the gas mixture comprising a physiologically acceptable gas selected from the group consisting of SF6, CF4, CBrF3, C4F8, CClF3, C2F6, C2ClF5, CBrClF2, C2Cl2F4 and C4F10, said gas or at least a gas in said gas mixture being such that, under standard conditions, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25 Torr.

29. An aqueous suspension made according to the method of claim 26, wherein the physiologically acceptable gas is such that, under standard conditions, and at a rate of pressure increase to the suspension of about 100 Torr/min, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25 Torr.

30. An aqueous suspension made according to the method of claims 27 or 28, wherein the physiologically acceptable gas is such that, under standard conditions, and at a rate of pressure increase to the suspension of about 100 Torr/min, the pressure difference ΔP between pressures at which the bubble counts are about 75% and 25% of the original bubble count is at least 25 Torr.

31. The method of claims 1 or 15, wherein the physiologically acceptable gas is selected from the group consisting of CF4, C2F6, C4F8, or C4F10.

32. The method of claim 1, wherein the physiologically acceptable gas is CF4.

33. The method of claim 1, wherein the physiologically acceptable gas is C2F6.

34. The method of claim 1, wherein the physiologically acceptable gas is C4F8.

35. The method of claim 1, wherein the physiologically acceptable gas is C4F10.

36. The method of claim 1, wherein the physiologically acceptable gas is SF6.

37. The method of claims 16 or 17, wherein the physiologically acceptable gas is selected from the group consisting of CF4, C2F6, C4F8, or C4F10.

38. The method of claim 16, wherein the physiologically acceptable gas is CF4.

39. The method of claim 16, wherein the physiologically acceptable gas is C2F6.

40. The method of claim 16, wherein the physiologically acceptable gas is C4F8.

41. The method of claim 16, wherein the physiologically acceptable gas is C4F10.

42. The method of claim 16, wherein the physiologically acceptable gas is SF6.

43. The method of claim 1, in which at least part of the phospholipids are in the form of liposomes.

44. The method of claim 15, in which at least part of the phospholipids are in the form of liposomes.

Referenced Cited
U.S. Patent Documents
3615972 October 1971 Morehouse et al.
3650831 March 1972 Jungermann
3900420 August 1975 Sebba
3968203 July 6, 1976 Spitzer
4027007 May 31, 1977 Messina
4192859 March 11, 1980 Mackaness et al.
4224179 September 23, 1980 Schneider
4229360 October 21, 1980 Schneider
4235871 November 25, 1980 Papahadjopoulos et al.
4256251 March 17, 1981 Moshofsky
4265251 May 5, 1981 Tickner
4276885 July 7, 1981 Tickner et al.
4316391 February 23, 1982 Tickner
4370349 January 25, 1983 Evans
4442843 April 17, 1984 Rasor
4466442 August 21, 1984 Hilmann et al.
4544545 October 1, 1985 Ryan
4572203 February 25, 1986 Feinstein
4657756 April 14, 1987 Rasor
4681119 July 21, 1987 Rasor
4684479 August 4, 1987 D'Arrigo
4718433 January 12, 1988 Feinstein
4774958 October 4, 1988 Feinstein
4832941 May 23, 1989 Berwing
4844882 July 4, 1989 Widder et al.
4859363 August 22, 1989 Davis
4900540 February 13, 1990 Ryan et al.
4927623 May 22, 1990 Long
4957656 September 18, 1990 Cerny
5049322 September 17, 1991 Fiessi
5088499 February 18, 1992 Unger
5089181 February 18, 1992 Hauser
5123414 June 23, 1992 Unger
5137928 August 11, 1992 Erbel
5141738 August 25, 1992 Rasor
5147631 September 15, 1992 Glajch et al.
5149319 September 22, 1992 Unger
5190982 March 2, 1993 Erbel
5195520 March 23, 1993 Schlief
5205287 April 27, 1993 Erbel
5209720 May 11, 1993 Unger
5228446 July 20, 1993 Unger
5271928 December 21, 1993 Schneider
5283067 February 1, 1994 Geller
5312615 May 17, 1994 Schneider
5352436 October 4, 1994 Wheatley
5364612 November 15, 1994 Goldenberg
5380411 January 10, 1995 Schlief
5380519 January 10, 1995 Schneider
5393524 February 28, 1995 Quay
5409688 April 25, 1995 Quay
5413774 May 9, 1995 Schneider
5425366 June 20, 1995 Reinhardt
5445813 August 29, 1995 Schneider
5501863 March 26, 1996 Rössling et al.
5529766 June 25, 1996 Klaveness
5531980 July 2, 1996 Schneider et al.
5536489 July 16, 1996 Lohrmann
5536490 July 16, 1996 Klaveness
5552133 September 3, 1996 Lambert et al.
5556610 September 17, 1996 Yan et al.
5558856 September 24, 1996 Klaveness et al.
5567413 October 22, 1996 Klaveness
5567414 October 22, 1996 Schneider
5593687 January 14, 1997 Rössling et al.
5599523 February 4, 1997 Beller
5601085 February 11, 1997 Østensen
5639443 June 17, 1997 Schutt et al.
5643553 July 1, 1997 Schneider
5658551 August 19, 1997 Schneider
5670135 September 23, 1997 Schroder
5711933 January 27, 1998 Bichon et al.
5716597 February 10, 1998 Lohrmann et al.
5730954 March 24, 1998 Albayrak et al.
5776429 July 7, 1998 Unger et al.
5874062 February 23, 1999 Unger
Foreign Patent Documents
1232837 February 1988 CA
1239092 July 1988 CA
2077383 March 1993 CA
A 41 27 442 February 1993 DE
A 131 540 January 1985 EP
0 245 019 November 1987 EP
327490 February 1989 EP
0 324 938 July 1989 EP
A 324 938 July 1989 EP
359 246 March 1990 EP
359 246 March 1990 EP
458079 April 1991 EP
A 458 745 November 1991 EP
0 467 031 January 1992 EP
A 554 213 April 1993 EP
1044680 October 1966 GB
213 5647 September 1984 GB
253115 January 1996 NZ
WO-A-80/2365 November 1980 WO
WO 80/02365 November 1980 WO
WO 84/02838 August 1984 WO
WO-A-85/02772 July 1985 WO
WO 88/7365 October 1988 WO
WO 89/05160 June 1989 WO
WO 89/06978 August 1989 WO
WO 89/10118 November 1989 WO
WO 91/09629 July 1991 WO
WO 91/12823 September 1991 WO
WO 91/15244 October 1991 WO
WO 92/05806 April 1992 WO
WO 92/17212 October 1992 WO
WO A 92/17212 October 1992 WO
WO 92/17213 October 1992 WO
WO 92/17514 October 1992 WO
WO 92/18164 October 1992 WO
WO 92/19273 November 1992 WO
WO 92/21382 December 1992 WO
WO 92/22247 December 1992 WO
WO 93/5819 April 1993 WO
WO93/05819 April 1993 WO
WO 93/06869 April 1993 WO
WO 93/17718 September 1993 WO
WO 94/16739 August 1994 WO
Other references
  • Epstein et al., J. Chem. Physics Nov. 1990.
  • Swanson, Pharmaceuticals in Medical Imaging; MacMillan Publishing, NY pp 682-687 (1990).
  • Lincoff et al., Arch. Opthamology 98:1610-1611 (1980).
  • Lincoff et al., Arch. Opthamology 98:1646 (1980).
  • Jacobs, Current Eye Research, 5(8):575-578 (1986).
  • Gardner et al., Arch Opthalmol. 106:1188-1189 (1988).
  • Dupont Technical Bulletin (El Dupont De Nemours, Wilmington, DE) pp 1-10 (1987).
  • Gregoriadis, Gregory, Liposome Technology, vol. I, “Preparation of Liposomes”, CRC Press, pp. 172-177, 1984.
  • Biochemistry/Ed. Stryer—2 Ed., San Francisco, Freeman, pp. 208-209 (1981).
  • Concise Encyclopedia Of Polymer Sci. and Engin., Wiley, pp. 12-13 (1990).
  • Encyclopedia of Polymer Science and Engineering, 2nd ed., 10, p. 95, Wiley & Sons, (1987).
  • Encyclopedia of Polymer Science and Engineering, pp. 164-169, Wiley & Sons, 1985.
  • ““Freon” Fluorocarbons Properties and Applications,” DuPont Technical Bulletin, pp. 1-11 (1964).
  • “Freon” DuPont Technical Bulletin, pp. 1-10 (1987).
  • Gas Encyclopedia, Elsevier Publishier (1976), CCIF3.
  • Handbook of Pharmaceutical Excipients: Am. Pharm. Ass. 181-183 (1986).
  • “Lecithin” in Rompp Chemie Kexikon, p. 2474 (1989-92).
  • “Lecithin” in Blakiston's Gould Medical Dictionary, 4th Ed., N.Y., McGraw-Hill, p. 749 (1979).
  • “Lecithin” in Dorland's Illustrated Medical Dictionary, 26 Ed., Philadelphia, Saunders, p. 721 (1981).
  • Remington's Pharmaceutical Sciences: Mack Publ. Comp., 295-298: 736; 1242-44 (1975).
  • Barnhart et al., Invest. Radiol, 25, 162-164 (1990) “Characterics of Albunex”.
  • Benita et al., Journal of Pharmaceutical Science, 73, pp. 1721-1724 (1984) “Characterization of Drug Loaded Polydilactide Microspheres”.
  • Bleeker, et al., J. Acoust. Soc. Am., 87 (4), Apr. 1990, pp. 1792-1797, “Ultrasonic characterization of Albunex® . . . ”.
  • Bleeker, et al., 1990 J. Ultrasound Med., 9:461-471, (1999), “On the Application of Ultrasonic Contrast Agents . . . ”.
  • Bommer et al, Abstract of the 54 Scient. Session Circulation 64,—203, Abst. 770 (1981).
  • Crommelin et al., Pharm. Res., pp. 159-163 (1984) “Stability of Liposomes on Storage . . . ”.
  • Crommelin et al., Liposomes as Drugs Carriers Symp., pp. 88-93 (1986) “Freezing and Freeze Drying of Liposomes”.
  • de Gruyter, “Phospholipids”, Concise Encyclopedia of Biochemistry, Berlin, pp. 348-349 (1983).
  • deJong, et al., Ultrasonics, 1992, vol. 30, No. 2, pp. 95-103, “Absorption and scatter of encapsulated gas filled microspheres . . . ”.
  • deJong, et al., Ultrasonics, 1991, vol. 29 Jul., pp. 324-330, “Principles and recent developments in ultrasound”.
  • Edwards, et al. J. Acoust. Soc. Am., vol. 70, No. 3 (1983), “Scattering of focused ultrasound by spherical microparticles”.
  • Epstein, et al., J. Chem. Physics, vol. 18, No. 11, pp. 1505-1509, Nov. 1950, “On the Stability of Gas Bubbles in Liquid-Gas Solutions”.
  • Feinstein, et al., JACC, vol. 16, No. 2, 8/90:316-24, “Safety and Efficacy of a New Transpulmonary Ultrasound Agent . . . ”, Amer. Hearts Assn. Monograph Circulation, Part II, vol. 72, No. 4, Oct. 1985, Abstracts of the 58th Scientific Ses.
  • Feinstein, et al., Am. J. of Physiologic Imaging, 1:12-18 (1986), “Myocardial Contrast Echocardiography . . . ”.
  • Feinstein, J. of the Amer. Coll. of Cardiol, 8:251-253 (1986) “Myocardial Perfusion Imaging . . . ”.
  • H. Fessi, et al., “Nanocapsule formation by interfacial polymer deposition . . . ,” Int. J. Pharm., 1989, vol. 55, No. 1, pp. R1-R4.
  • Fieser and Fieser, Organic Chemistry, 3rd ed. (1956) p. 847.
  • Fobbe, et al., Furtschr Rontgenstr, 154.3 (1991) 242-245, “Farbkodierte Duplexsonographic und Ultraschallkontrast mittel . . . ”.
  • Ganguly et al., “Structure of hollow polystyrene microspheres . . . ” J. Microencapsulation, vol. 6, No. 2, 193-198 (1989).
  • Gardner, et al., (1988), “A Survey of Intraocular Gas Use in North America,” Arch. Ophthalmol., 106:1188-1189.
  • Goldberg et al., Radiology, 177, pp. 713-717 (1990) “Hepatic Tumors . . . ”.
  • Helzel, Fortschr. Rontgenste, 140, pp. 337-340 (1984) “Erste Erfahrurgen . . . ”.
  • Henry-Michelland et al., Colloids and Surfaces, 14, pp. 269-276 (1985) “Lyophilization and Rehydration of Liposomes”.
  • Jacobs, “Intraocular gas measurement using A-scan ultrasound,” Current Eye Research, vol. 5, No. 8, 1986, pp. 575-578.
  • Keller et al, Circulation Res, 65, 458-467 (1989) “The Behavior of Sonicated Albumin . . . ”.
  • Krause et al., International Journal of Pharmaceutics., 27, pp. 145-155 (1985) “Polylactic acid nanoparticle . . . ”.
  • Levene et al, J. Acoust. Soc. Am., 87 (Suppl) 69 (1990) “Characterization of Albunex . . . ”.
  • Lincoff, et al., Intravitreal Longevity of Three Perfluorocarbon Cases, Arch. Ophthalmology, 98:1610-1611 (1980).
  • Lincoff, et al., “Intravitreal Expansion of Perfluorocarbon Bubbles,” Arch. Ophthalmology, 98:1646 (1980).
  • Lincoff, et al. “The Perfluorocarbon Gases in the treatment of Retinal Detachment,” Ophthalmology, 90(5):546-551 (1983).
  • Lincoff, et al., “Perfluoro-n-butane: A Gas for Maximum Duration Retinal Tamponade,” Arch. Ophthalmology, 101:460-463 (1983).
  • K. Makino, “Preparation and in vivo degradation properties . . . ,” Chem. Pharm. Bull., (1985), vol. 33, No. 3, pp. 1195-1201.
  • Mattrey et al., Radiology, 148, pp. 759-762 (Dec. 1982) “UHM Sound; Perfluoroctylbromide . . . ”.
  • Chem Abs., vol. 102. No. 3, 21 (Jan. 1985), Maynard et al., “Ultrasonic absorption by liposomes”.
  • Meltzer, et al., Ultrasound in Med. & Biol., vol. 7, No. 4, pp. 377-384, 1981, “Transmission of Ultrasonic Contrast Through the Lungs”.
  • Miller et al., J. Amer. Soc. Anesthesiol., 36 339-351 (1971) “Physicochemical Approaches . . . ”.
  • Möhwald, Annu. Rev. Phys. Chem., 41, 441-76 (1990) “Phospholipid and Phospholipid-Protein Monolayers At The Air/Water Interface”.
  • Murrell et al, “Properties of liquids and solutions”, Wiley, p. 276 (1982).
  • Nomura, et al., “US Contrast Enhancement of Hepatic Tumor with Helium Gas Microbubbles: A Preliminary Report,” Jpn. J. Med. Ultrasonics, vol. 18, No. 5, 1991, pp. 444-450.
  • O'Hara et al., Journal of Membrane Science, 23 (1985) 1-9, “Preparation of ethylcellulose . . . ”.
  • Ohta, et al., Jpn. J. Med. Ultrasonics, vol. 18, No. 4 (1991), “Effect of the Contrast Agent and the Agitation Met.”
  • Ophir, et al., Ultrasound in Med. &Biol., vol. 15, No. 4, pp. 319-333, 1989, “Contrast Agents in Diagnostic Ultras.”
  • Ostro in Spektrum d. Wiss, 94-95, 98 (Marz 1987). “Liposomen . . . ”.
  • Özer et al., Acta Pharm. Tech. 34, pp. 129-139 (1988) “Influence of Freezing and Freeze Drying on Stability of Liposome . . . ”.
  • Park, et al., Journal of Chemical And Engineering Data, vol. 27, No. 3 (1982), “Solubility of Gases in Liquids. 14. Bunsen Coefficients for Several Fluorine-Containing Gases (Freons) Dissolved in Water at 298.15K”.
  • Peters et al., Am. J. Ophthalmol. 100 pp. 831-839 (1985) “The non expansive, equilibrated concentration of perfuoropropane in the eye”.
  • Puisieux et al., Bull. Soc. Pharm. Bordeaux, 123, pp. 111-126 (1984) “Les Liposomes . . . ”.
  • Rompp Lex. Chemie. 8 Aufl. Stuttgart: Franckh; Bd. Z: Cm-G, (1981): Bd 3; H-L, (1983); Bd 4, M-Pk (1985) “Porositat”.
  • Schlief, Current Opinion in Radiology, 1993, 3:198-207, “Ultrasound Contrast Agents”.
  • Schneider, et al., Investigative Radiol., 26(1), pp. S190-S191 (1991) “A New Ultrasound Contrast Agent Based on Biodegrabable Polymers Microballoon”.
  • Schneider, et al., Investigative Radiol., 29(2), pp. S149-S151 (1991) “The Use of Polymers Microballoons as Ultrasound Contrast Agent . . . ”.
  • Swanson, pp. 682-687, “Chapter 22: Enhancement Agents for Ultrasound: Fundamentals,” Pharmaceuticals In Medical Imaging, (1990).
  • Szoka et al, PNAS 75, pp. 4194-4198 (Sep. 1978) “Procedure for preparation of Liposomes . . . ”.
  • Tomlinson, Int J. Pharm. Tech. & Prod. Mfr., pp. 49-57 (1983) “Microsphere Delivery Means . . . ”.
  • Ulmius et al, Biochem., 21, p. 1553 (1982) “Molecular organization . . . ”.
  • K. Uno, et al., “A new method of preparing monocored . . . ,” J. Microencapsulation, 1984, vol. 1, No. 1, pp. 3-8.
  • Violante, et al., Investigative Radiology, vol. 26, Nov. Supp 1991, “Particle-Stabilized Bubbles for Enhanced Organ Ultrasound Imaging”.
  • Voigt et al., “Lzithine” in Lehrb. d. pharm. Tech. i, uberab. Aufl.—Weinheim; VCH, p. 367 (1979).
  • Wheatley et al, Biomaterials 11, pp. 713-717 (1990) “Contrast agents for diagnostic ultrasound . . . ”.
  • Widder, et al. AJR:147, Aug. 1986, “Microbubbles as Contrast Agent for Neurosonography and Ultrasound . . . ”.
  • Zhang, et al., J. East China Inst. Chem. Tech., 12(3) 343-345 (1986) “A Study on the Solubilities of F22 and C2F4 in Aqueous Solutions of HCI and NacI”.
  • Zeghlouol et al, Journal de Chimie Physique, 83; 665-671 (1986) “NMR And Microcalorimetry Study Of The Solubility Of Certain Halons And Their Interaction with Human Serum Albumin”.
  • deJong et al Ultrasonics 1992 vol. 30 No. 2 pp 95-103 Absorption and scatter of encapsulated gas etc.
  • deJong et al Ultrasonics 1991 vol. 29 July pp 324-330 Principles and recent developments in ultrasound etc.
  • Bleeker et al 1990 J. Ultrasound Med 9:461-471, 1990 pp 462-471 On the Application of Ultrsonic Contrast etc.
  • Feinstein et al JACC vol. 16, No. 2 8/90:316-24 Safety and Efficacy of a New Transpulmonary Ultrasound etc.
  • Amer Hearts Assn Monograph Circulation Part II vol. 72 No. 4 10/85 Abstracts of the 58th Scientific Sessions.
  • Bleeker et al J. Acoust. Soc. Am. 87 (4) 4/90 pp 1792-1797 Ultrasonic characterization of Albunex® etc.
  • Epstein et al J. Chem. Physics vol. 18, No. 11, 11/50 On the Stability of Gas Bubbles in Liquid-Gas Solutions.
  • Meltzer et al Ultrasound in Med & Biol vol. 7, No. 4 pp 377-384 1981 Transmission of Ultrasonic Contrast etc.
  • Violante et al Investigative Radiology vol. 26 Nov. Supp 1991 Particle-Stabilized Bubbles for Enhanced etc.
  • Ohta et al Jpn J Med Ultrasonics vol. 18 No. 4 (1991) Effect of the Contrast Agent and the Agitation Method etc.
  • Feinstein et al Am J of Physiologic Imaging 1:12-18 (1986) Myocardial Contrast Echocardiography etc.
  • Widder et al AJR:147, 8/86 Microbubbles as a Contrast Agent for Neurosonography and Ultrasound- etc.
  • Schlief Current Opinion in Radiology 1991, 3:198-207 Ultrasound Contrast Agents.
  • Fobbe et al Furtschr Rontgenstr 154.3 (1991)242-245 Farbkodierte Duplexsonographic und Ultra- etc.
  • Ophir et al Ultrasound in Med & Biol vol. 15 No. 4 pp 319-333 1989 Contrast Agents in Diagnostic Ultrasound.
Patent History
Patent number: RE39146
Type: Grant
Filed: Jul 15, 1998
Date of Patent: Jun 27, 2006
Assignee: Bracco International B.V. (Amsterdam)
Inventors: Michel Schneider (Troinex), Feng Yan (Grand-Lancy), Nadine Garcel (Segny), Jerome Puginier (Caslano), Marie-Bernadette Barrau (Geneva), Philippe Bussat (Feigeres), Eva Hybl (Geneva), Daniel Bichon (Saint Gely du Fesc), Pascal Grenier (Segny)
Primary Examiner: Michael G. Hartley
Attorney: Nixon & Vanderhye P.C.
Application Number: 09/115,963
Classifications
Current U.S. Class: Liposome Containing (424/9.51); Stable Gas Bubbles Containing Or Intentional Solubilized Gas Containing (424/9.52); Having B-scan And Doppler (600/441); Contrast Enhancement (600/458)
International Classification: A61K 49/00 (20060101); A61B 8/00 (20060101);